A phase 1/2 trial of DC05F01 in ovarian cancer and small-cell lung cancer, run by Heronova Pharmaceuticals, now recruiting.
A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06873555 by Heronova Pharmaceuticals, with 60 participants planned, started 2024-09-11 and due to reach its primary completion in 2027-12. Interventions recorded: DC05F01.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.